BioSpace is the digital hub for life sciences news and jobs. Our mission is to provide essential insights, tools, and opportunities to connect the innovative organizations and talented professionals who advance health and quality of life across the globe.

2024年10月29日 · Under the partnership, Texas Biomed will deliver preclinical research and resources to help develop vaccines for reducing global epidemic and pandemic risks.

2025年1月22日 · The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against its limits after racking up around 50 approvals since getting its first FDA nod in September 2014.

2024年12月19日 · Bristol Myers Squibb grabbed headlines in April when it announced it would eliminate 2,200 jobs by the end of 2024 in an effort to generate about $1.5 billion in cost savings. The company hopes to optimize operations by reducing management layers, among other cost-cutting measures, according to its investor presentation.BMS also noted it would prioritize …

BioSpace is the digital hub for life science news and jobs.We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

2024年11月19日 · While CAR T cell therapies are pricey—BMS’s Breyanzi is over $480,000 for one suspension—the potential to have a one-time infusion for a long-lasting, drug-free remission would be highly appealing to lupus patients who otherwise face a lifetime of ongoing medications, Badyal said. Companies working in this space will need to consider how they can make these …

2025年1月3日 · 2024 was a tough year for the biopharma industry, with several companies including Bayer, Bristol Myers Squibb and Johnson & Johnson are cutting hundreds or even thousands of employees.. BioSpace will continue to be your source of news on job cuts and restructuring initiatives throughout 2025. Follow along as we keep you up to date on which …

2024年3月18日 · Despite facing challenging market constraints throughout 2023, which led to strings of layoffs and slowed hiring, salaries for the biopharma industry experienced modest growth with industry average salaries higher than ever before.

2025年1月21日 · The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic colorectal cancer, but in its approval announcement, the FDA pointed to significant improvements in progression-free survival, calling it the “major efficacy outcome” of the trial.

2010年12月11日 · Atara Biotherapeutics’ layoffs could leave the biotech with around 80 employees. The cuts follow news that the FDA rejected Ebvallo, a T cell therapy approved in Europe for a transplant-related blood cancer, and placed a clinical hold on the company’s active drug applications.